Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Atrium Therapeutics, Inc.

35 indications, side-by-side phase, drug & LoA

$12.37

-0.06 (-0.48%)

B 63Pipeline Score Undervalued Biotech · Clinical
Market Cap
223.91 M
EPS
-
P/E Ratio
-
Value Trade
1.83 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    19.64 M

  • R&D Expenses

    16.66 M

  • Operating CF

    -31.14 M

  • Total Assets

    292.36 M

  • Total Liabilities

    58.26 M

  • Equity

    234.10 M

  • D/E Ratio

    12,345

-2.89 %
Week
-3.82 %
1 Month
-10.22 %
3 Month
-10.22 %
6 Month
-10.22 %
5 Year
-10.22 %
All Time
Cash Data
Healthy

  • Cash Position

    267.85 M

  • Monthly Burn

    10.38 M

  • Runway

    24.9 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 14, 2026
Overview
Volume
103.63 K
52 Week Range
11.95 - 16.77
% held by Insiders
0.22 %
% held by Institutions
86.52 %
Enterprise Value
-41.26 M
Total Shares
17.12 M
Short %
22.49 %
Float Shares
16.24 M
Company Description
HQ: 3020 CALLAN ROAD, SAN DIEGO, C...
Employees:391
https://www.aviditybiosciences...

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
IND Submission example
ATR 1072 PRKAG2 syndrome
IND
—
RNA-Based Therapies
Rare Diseases
ATR 1072 PRKAG2 syndrome
IND
—
RNA-Based Therapies
Rare Diseases
ATR 1072 PRKAG2 syndrome
IND
—
RNA-Based Therapies
Rare Diseases
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
B63
Pipeline Score
$1.2B
Pipeline Value
Undervalued
Valuation Signal
12
Drugs Scored
5.4x
rNPV / MCap
Top 89%
Micro Cap
(rank 101 of 905)
Percentile Rank
Atrium Therapeutics, Inc. holds a solid B-grade pipeline (63/100), with $4.9B risk-adjusted pipeline value, led by Nivolumab in Multiple Myeloma (Phase 2).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Nivolumab
Small molecule		Multiple MyelomaPhase 2NCT0652362119% $921M ACTIVE NOT_RECRUITING 1 - -Dec 1, 2028 -
May 21, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
del-zota
Duchenne muscular dystrophy (DMD)
Phase 1/2
2025-07-23
del-zota
Duchenne muscular dystrophy (DMD)
Phase 1/2
2025-07-23
del-zota
Duchenne muscular dystrophy (DMD)
Phase 1/2
2025-07-23
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in RNA
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
RNA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RNA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RNA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
RNA Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
RNA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Atrium Therapeutics, Inc. (RNA) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How RNA ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Rare Neurological Disorders #17 of 46 PHASE 3 AOC 1001
IONS BIIB SRPT
$139.4B 0 FOLLOWER